Wesley Research Institute
Donate
Now

Myositis is a disorder in which the immune system attacks the muscles. It is hoped that this new treatment may help improve the symptoms of this disease.

 

Research Objectives

Status

Current

Recruitment

Closed

Patient Group

Idiopathic Inflammatory Myopathy/Myositis Status: Current

Study location

Wesley Research Institute

Phase

3

Study type

Industry Sponsored
Sponsors: Argenx BV (global) and ICON Clinical Research Pty Ltd (Local)

Lead investigator

  • Dr Daman Langguth

Clinical trial coordinator

  • Venita Bali

Technical title

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathies

About this research project

The research project is testing a new treatment for Active Idiopathic Inflammatory Myopathy. This is a disorder in which the immune system attacks the muscles. This leads to muscle weakness and may affect other organs of the body.

The potential new treatment being tested is called efgartigimod (also called ARGX113). It is hoped that efgartigimod may help improve the symptoms of myositis.

 

Latest News

Michel’s story: A father, a friend and a voice for cancer research 

Research has helped Michel Itel OAM keep looking towards a future with his family. Through his connection with Wesley Research Institute, he is helping researchers understand what that future means to people living with cancer.

Mapping cancer cell by cell: meet Associate Professor Arutha Kulasinghe 

Associate Professor Arutha Kulasinghe, uses spatial biology to map cancer one cell at a time, with the goal of matching every patient to the treatment that will work for them.

Webinar- Coeliac Disease: Rethinking Gluten Thresholds

Watch the latest coeliac disease webinar, deep diving into the findings from the Gluten Threshold Study.
1 2 3 … 40
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram